371 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
ACN Accenture plc $171.04 $109.71B N/A
Article Searches
Stock Market News for April 04, 2017 http://www.zacks.com/stock/news/255225/stock-market-news-for-april-04-2017?cid=CS-ZC--255225 Apr 04, 2017 - Benchmarks closed in the red on Monday, dragged down by weak auto sales data and a dip in manufacturing growth rate
What's Behind Computer Sciences' (CSC) Recent Momentum? http://www.zacks.com/stock/news/254839/whats-behind-computer-sciences-csc-recent-momentum?cid=CS-ZC-FT-254839 Mar 31, 2017 - Computer Sciences Corporation (CSC) has gained solid momentum recently, with shares gaining over 4.5% in the last three trading days.
Computer Sciences' Shareholders Approve Merger with HPE http://www.zacks.com/stock/news/254469/computer-sciences-shareholders-approve-merger-with-hpe?cid=CS-ZC-FT-254469 Mar 29, 2017 - Computer Sciences Corporation (CSC) announced that the majority of its shareholders have approved its merger with HPE's Enterprise Services business.
Allergan Acne Candidate Meets Endpoints in Phase III Studies http://www.zacks.com/stock/news/254397/allergan-acne-candidate-meets-endpoints-in-phase-iii-studies?cid=CS-ZC-FT-254397 Mar 28, 2017 - Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline
Foamix Pharma's FMX101 shows mixed results in two late-stage acne studies; shares plummet 47% premarket https://seekingalpha.com/news/3253525-foamix-pharmas-fmx101-shows-mixed-results-two-late-stage-acne-studies-shares-plummet-47?source=feed_news_all Mar 27, 2017 - Thinly traded micro cap Foamix Pharmaceuticals (NASDAQ:FOMX) craters 47% premarket on light volume in response to its announcement of mixed results from two Phase 3 clinical trials assessing
Allergan's oral antibiotic successful in two late-stage acne studies https://seekingalpha.com/news/3253500-allergans-oral-antibiotic-successful-two-late-stage-acne-studies?source=feed_news_all Mar 27, 2017 - Two Phase 3 clinical trials assessing Allergan's (NYSE:AGN) orally administered sarecycline in people with moderate-to-severe acne met their 12-week primary efficacy endpoints. Based on the successful
Xenon Pharma's lead dermatology candidate flunks mid-stage acne study http://seekingalpha.com/news/3253267-xenon-pharmas-lead-dermatology-candidate-flunks-mid-stage-acne-study?source=feed_news_all Mar 24, 2017 - Thinly traded micro cap Xenon Pharmaceuticals (NASDAQ:XENE) is poised for a down day after announcing that lead dermatology candidate XEN801 failed to beat placebo in a Phase 2 clinical trial in peopl
Company News for March 24, 2017 http://www.zacks.com/stock/news/254070/company-news-for-march-24-2017?cid=CS-ZC--254070 Mar 24, 2017 - Companies in the News are: CTAS,ACN,CAG,FIVE
Accenture's (ACN) CEO Pierre Nanterme on Q2 2017 Results - Earnings Call Transcript http://seekingalpha.com/article/4057500-accentures-acn-ceo-pierre-nanterme-q2-2017-results-earnings-call-transcript?source=feed_tag_transcripts Mar 23, 2017 - Accenture plc (NYSE:ACN) Q2 2017 Results Earnings Conference Call March 23, 2017, 08:00 AM ET Executives Angie Park - Managing Director and Head of Investor Relations Pierre Nanterme - Chairman and CE
Accenture (ACN) Q2 Earnings Top Estimates, Revenues Miss http://www.zacks.com/stock/news/253897/accenture-acn-q2-earnings-top-estimates-revenues-miss?cid=CS-ZC-FT-253897 Mar 23, 2017 - Accenture plc (ACN) reported mixed second-quarter fiscal 2017 results.

Pages: 1...2829303132333435363738

<<<Page 33>